The Maine Cancer Genomics Initiative (MCGI) is an alliance of Maine oncology providers led by The Jackson Laboratory with funding from the Harold Alfond™ Foundation. Its primary goal is to reduce disparities in access to advanced technologies for cancer care and precision medicine.
Want to learn more?
Contact UsMCGI, in partnership with every oncology practice in Maine, has provided innovative cancer genomic testing, education and clinical trials infrastructure to one of the most rural areas in the country. Now, MCGI has become a model for community precision oncology, or personalized cancer care, in a rural setting.
Latest News
-
Blog PostMay 04, 2023Advancing cancer research with the latest therapies
Improving cancer patient outcomes depends on expanding our understanding of basic cancer biology as well as improving patient access to the latest therapies. -
Press ReleaseDecember 19, 2022An outstanding year of growth at The Jackson Laboratory
2022 has been a notable year for The Jackson Laboratory, with great achievements and many reasons to celebrate continued momentum for JAX’s mission. -
Featured ArticleSeptember 15, 2022JAX undertakes nationwide study to evaluate impact of genomic tumor boards on cancer care
The Jackson Laboratory announced today that it will take its cornerstone genomic tumor board program to oncologists across the nation as part of a SWOG Cancer Research Network study, in collaboration with Columbia University. -
Featured ArticleFebruary 01, 2022MCGI: A 'game changer' for cancer patients
The Maine Cancer Genomics Initiative is raising awareness of, and access to, advanced genomic treatments all across Maine.
-
Blog PostJanuary 09, 2023MCGI: Meet the team
Learn more about the JAX MCGI team, including roles and fun facts. -
Press ReleaseOctober 24, 2022JAX participates in A Day of Hope for Maines cancer fighters
Eight team members who make up JAX's MCGI recently attended MaineGeneral's annual Day of Hope Event at the Augusta Civic Center. -
Featured ArticleJune 28, 2022JAX Genomic Medicine is increasing the precision of brain cancer diagnoses
The new technique of methylome profiling, now available from The Jackson Laboratory, provides more precise tumor classification for cancers of the central nervous system (CNS). -
Press ReleaseOctober 14, 2021JAX appoints first ever Chief Medical Officer, Jens Rueter
Jens Rueter, M.D. has been appointed the first ever chief medical officer of The Jackson Laboratory. Rueter is a practicing physician in Maine and has served as medical director of JAX’s Maine Cancer Genomics Initiative (MCGI) for the past five years.